New shot targets Hard-to-Treat cancers: early trial opens
NCT ID NCT07231211
First seen Nov 17, 2025 · Last updated May 03, 2026 · Updated 21 times
Summary
This study tests a new drug called SHR-4610 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding the safest dose, then checking if it shrinks tumors or slows their growth. About 258 adults aged 18-75 with measurable tumors and good daily function can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.